Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Iovance Biotherapeutics progresses on BLA for lifileucel, faces recruitment challenges

Iovance Biotherapeutics is on track with BLA completion expected this quarter, strong pipeline progress, and manufacturing capacity expansion. Challenges include study recruitment uncertainties and the ongoing CEO search. Opportunities exist in new program data releases, European expansion, and pivotal study enrollment.

Iovance Biotherapeutics advances TIL therapy pipeline with strong financials

Iovance Biotherapeutics is on track with key milestones in TIL therapy development and commercialization.
The company's financial position is stable, with strategic investments supporting future growth.
Challenges include operational efficiency, FDA interactions, and trial progress management.
Opportunities lie in international trials, market expansion, and revenue growth post-launch.

Iovance Biotherapeutics reports Q2 loss, eyes lifileucel FDA review

Iovance Biotherapeutics faces financial challenges with a significant net loss in Q2 2023, despite positive milestones and revenue from Proleukin sales.
The company's TIL therapy pipeline shows promise with progress in key clinical trials, while opportunities exist for market differentiation and revenue growth.
Challenges include ongoing financial losses, longer timelines for pivotal studies, and potential delays in trial enrollment, requiring strategic management.

Iovance Biotherapeutics progresses on Lifileucel commercialization and pipeline expansion

Iovance Biotherapeutics is making significant strides in advancing its pipeline and commercialization efforts, with a strong focus on FDA approval for Lifileucel and expanding into key markets. The company faces challenges in labeling discussions and efficacy benchmarks but has opportunities in European marketing, new therapy programs, and potential partnerships for international growth.

Iovance Biotherapeutics excels with Amtagvi approval and clinical progress

Iovance Biotherapeutics showcased strong performance with the FDA approval of Amtagvi and progress in clinical trials, positioning the company for growth.
While facing challenges in scaling operations and regulatory hurdles, the company's focus on efficiency and clinical research strengths bode well for the future.
With opportunities in label expansion, market penetration, and revenue growth, Iovance is poised to capitalize on its innovative therapies and drive value for stakeholders.

Iovance Biotherapeutics reports Q1 loss, Amtagvi launch success

Iovance Biotherapeutics shows promising performance with a focus on Amtagvi's commercial success and pipeline advancements.
Strengths include positive reimbursement trends, successful patient selection processes, and efficient manufacturing operations.
Challenges lie in patient screening failures, financial clearance issues, and variability in bridging therapy usage.
Opportunities for growth include market expansion, high patient conversion rates, and accelerated submission processes for new therapies.

Iovance Biotherapeutics (IOVA) exceeds Q3 revenue targets, eyes global expansion

Iovance Biotherapeutics (IOVA) had a strong Q3 performance, exceeding revenue guidance and showcasing growth potential.
The company's focus on Amtagvi and global expansion presents opportunities for revenue diversification and market penetration.
Challenges lie in maintaining adoption rates, meeting revenue targets, and effectively managing increased manufacturing capacity.
Overall, IOVA's strategic initiatives position it for continued growth and success in the biopharmaceutical market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rumors of a buyout swirled around the biopharma.

Here's Why Iovance Biotherapeutics Jumped 51.3% in February

Cogent Communications Holdings

Campbell Soup

Gilead Sciences

Kroger

Newmont Mining

Regeneron Pharmaceuticals

iStar Inc

Virtu Financial

Vivint Smart Home Inc

The stock market in 2020 has gone from a raging bull market to panic mode in very short order.

10 Very Strong Stocks Thriving in a Very Crummy Stock Market

Iovance Biotherapeutics: There Is A Significant Upside In This Stock

Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q4 2019 Results - Earnings Call Transcript

Bloomberg reports that the company has been toying with the idea of a sale.

Here's Why Iovance Biotherapeutics Shares Soared as Much as 39.6%

Fate Therapeutics

These two companies are pushing the envelope of immunotherapies by developing unique cell types. Each has promising results for investors to consider.

2 Top Biotech  Stocks to Buy Right Now

- Biologics Licensing Application (BLA) submission planned for late 2020 -

Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel

The company announced a string of deals over the weekend that failed to spark investors' optimism.

Why Iovance Biotherapeutics Shares Dropped 11.8% Today

Shares of Iovance Biotherapeutics toppled Monday after the biotech company announced a gene-editing deal with Cellectis using TALEN technology. Cellectis stock also slipped.

Why This Biotech Stock Is Planning To Gene Edit Its Cancer Drugs

SAN CARLOS, Calif., Jan.  12, 2020  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company has obtained a license from Novartis to develop and commercialize an antibody cytokine engrafted protein, referred to as IOV-3001. Under the agreement, Iovance will pay an upfront payment to Novartis as well as low single digit milestones involved in initiation of patient dosing in various phases of clinical development for IOV-3001 and approval of the product in the U.S., EU and Japan. Novartis is also entitled to low-to-mid single digit royalties from commercial sales of the product.

Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog

Iovance Biotherapeutics Will Use TALEN® Technology from Cellectis to Develop Gene-Edited TIL Iovance Biotherapeutics Will Use TALEN® Technology from Cellectis to Develop Gene-Edited TIL

Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement

BioMarin Pharmaceutical

Immunomedics

Fast-approaching catalysts could make these biotech stocks top performers this year.

These 3 Biotech Stocks Could Be Top Stocks in 2020

The biopharma stock more than tripled in 2019.

Here's Why Iovance Biotherapeutics Jumped 21.2% in December

These companies are carving their own paths in cellular medicines. One just posted promising clinical results, while the other aims to do so this month.

2 Top Biotech Stocks to Buy in December

Iovance Biotherapeutics: Solving The Solid Tumors Conundrum

-  41 percent objective response rate (ORR) as assessed by the investigator in 42 patients who were primary refractory to anti-PD-1/L1 therapy -                - Median duration of response (DOR) was not reached as assessed by investigator at 12 months of study follow-up for the primary refractory subgroup -

Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy

Mirati Therapeutics

Personalis Inc

MIrati Therapeutics, Iovance Biotherapeutics, and Personalis are all using genetic knowledge to help find cures for cancer.

3  Cancer Treatment Stocks to Buy Right Now

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares jumped on Friday after the firm announced results from its mid-stage metastatic melanoma study at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Melanoma Treatment Takes a Big Step Forward

Iovance Biotherapeutics' (IOVA) CEO Maria Fardis on Q3 2019 Results - Earnings Call Transcript

We believe Iovance’s ORR and durability data for melanoma and cervical cancer is highly predictive of future success in the pivotal cohorts and will lead to approval.

TIL Death Do Us Part: CAR T History Foreshadows Iovance's Destiny For Outperformance

SAN CARLOS, Calif., Oct.  02, 2019  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that four abstracts highlighting its TIL therapy will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting from November 6-10, 2019 in National Harbor, Maryland. One of the abstracts is a late-breaking submission and presentation details will be made available to the public on November 1, 2019. Details on the three posters that will be presented as part of the regular submissions are below.

Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting

The company is flush with cash and wields a promising therapeutic pipeline. Is its recent tumble a buying opportunity?

Iovance Biotherapeutics: Buy the Dip?

Align Technology

Sarepta Therapeutics

The more disruptive the market is, the more we look for companies that are not affected by the daily sturm and drang of the news cycle because they have supply chain issues in China.

Top Baird Health Care and Biotech Picks Have Massive Upside Potential

SAN CARLOS, Calif., Aug.  26, 2019  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company plans to present at the following conferences in September:

Iovance Biotherapeutics to Present at Upcoming Investor Conferences in September

Iovance Biotherapeutics hit a "clear inflection point" in the second quarter, analysts said Friday — but that didn't stop the biotech stock from plunging on wider-than-expected losses.
The post Biotech Merger Activity Has Been Hot In 2019 — So, What's One More?

News for Iovance Biotherapeutics Stock (IOVA)